Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Dermapharm Holding SE (DMPHF) - Total Liabilities
Latest total liabilities as of September 2025: $1.47 Billion USD
Based on the latest financial reports, Dermapharm Holding SE (DMPHF) has total liabilities worth $1.47 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dermapharm Holding SE - Total Liabilities Trend (2013–2024)
This chart illustrates how Dermapharm Holding SE's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dermapharm Holding SE Competitors by Total Liabilities
The table below lists competitors of Dermapharm Holding SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cembre S.p.A. Ord
LSE:0DXU
|
UK | €64.27 Million |
|
Allgens Medical Technology Co. Ltd. A
SHG:688613
|
China | CN¥96.06 Million |
|
Luenmei Quantum Co Ltd
SHG:600167
|
China | CN¥4.37 Billion |
|
secunet Security Networks Aktiengesellschaft
F:YSN
|
Germany | €204.49 Million |
|
Mrs. Bectors Food Specialities Limited
NSE:BECTORFOOD
|
India | ₹4.54 Billion |
|
9ZX0
F:9ZX0
|
Germany | €759.75 Million |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
China | CN¥1.15 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Dermapharm Holding SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dermapharm Holding SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dermapharm Holding SE (2013–2024)
The table below shows the annual total liabilities of Dermapharm Holding SE from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.47 Billion | -8.91% |
| 2023-12-31 | $1.62 Billion | +83.52% |
| 2022-12-31 | $880.34 Million | -2.95% |
| 2021-12-31 | $907.13 Million | +0.81% |
| 2020-12-31 | $899.81 Million | +18.34% |
| 2019-12-31 | $760.38 Million | +69.54% |
| 2018-12-31 | $448.50 Million | +31.29% |
| 2017-12-31 | $341.62 Million | +36.16% |
| 2016-12-31 | $250.89 Million | -0.53% |
| 2015-12-31 | $252.22 Million | -14.96% |
| 2014-12-31 | $296.59 Million | -3.90% |
| 2013-12-31 | $308.62 Million | -- |